GMAB•benzinga•
CORRECTION: Genmab shares are trading lower after Johnson & Johnson decided not to exercise its option to receive a worldwide license to develop, manufacture, and commercialize HexaBody-CD38. Genmab will not pursue further clinical development.
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 10, 2025 by benzinga